Parameter	LEN + PEMBRO (N=355)	SUN (N=357)
Patients receiving any subsequent systemic anticancer therapy[a], n (%) Anti-VEGF PD-1/PD-L1 checkpoint inhibitor MTOR inhibitor CTLA-4 inhibitor Other	117 (33.0) 108 (30.4) 29 (8.2) 6 (1.7) 6 (1.7) 12 (3.4)	206 (57.7) 120 (33.6) 154 (43.1) 17 (4.8) 18 (5.0) 20 (5.6)
Median (range) time to next line therapy[b], mos	12.68 (1.45–37.36)	6.62 (0.39–28.52)
Median (range) duration of first subsequent anticancer therapy[c], mos	5.16 (0.10–30.23)	6.82 (0.03–30.72)
PFS2, median (95% CI)	Not reached (NE–NE)	28.7 mos (23.0–NE)
PFS2 HR (95% CI)	0.50 (0.39–0.65)	
Nominal *P* value	<0.0001	
PFS2 rate at 24/36 mos, % (95% CI)	72.7 (67.3, 77.4) / 61.9 (53.7, 69.0)	54.2 (48.4, 59.6) / 42.9 (32.8, 52.5)

[a]Monotherapy or in combination; [b]includes patients with available start date of first subsequent systemic anticancer medication; [c]includes patients with available start and end dates of first subsequent systemic anticancer medication. CI, confidence interval; HR, hazard ratio; LEN, lenvatinib; mos, months; NE, not estimable; PEMBRO, pembrolizumab; PFS2, progression-free survival on next-line therapy; SUN, sunitinib.